Athira Pharma IncNASDAQ:ATHANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6150
- TODAY'S CHANGE (%)-0.0249 (-3.8912%)
- Bid / Lots0.6150/ 2
- Ask / Lots0.6211/ 4
- Open / Previous Close0.6394 / 0.6399
- Day Range
- 52 Week Range
- Volume210,133
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATHA |
|---|---|---|
| 09:32 ET | 55994 | 0.621001 |
| 09:33 ET | 13379 | 0.615 |
Oct 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Athira Pharma Inc | 24.6M | -0.2x | --- |
RenovoRx Inc | 24.9M | -1.7x | --- |
Lisata Therapeutics Inc | 24.2M | -1.1x | --- |
Neurosense Therapeutics Ltd | 23.9M | -2.8x | --- |
X T L Biopharmaceuticals Ltd | 23.7M | -5.4x | --- |
Onconetix Inc | 24.1M | 0.0x | --- |
Company Information
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
Contact Information
- Headquarters
- 18706 North Creek Parkway Suite 104, Box 352141BOTHELL, WA, United States 98011
- Phone
- 425-620-8501
- Fax
- 302-636-5454
Executives
- Independent Chairwoman of the Board
- Kelly Romano
- President, Chief Executive Officer, Director
- Mark Litton
- Principal Financial Officer and Principal Accounting Officer
- Robert Renninger
- Chief People Officer
- Samantha Willing
- Chief Scientific Officer
- Kevin Church
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.78 |
EPS | $-2.97 |
Book Value | $3.41 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
